SCHEMBL24440968

SCHEMBL24440968

O=C(Nc1cc(Cl)c(O)c(Cl)c1)c1cccn1Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.58
CNR1 P21554 2/20 0.58
SCN3A Q9NY46 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 2/20 0.51
RAB9A P51151 1/20 0.51
DHODH Q02127 1/20 0.48
KDM4E B2RXH2 2/20 0.47
HTT P42858 1/20 0.46
POLB P06746 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
LMNA P02545 2/20 0.44
HSD17B13 Q7Z5P4 1/20 0.43
TP53 P04637 1/20 0.43
BRD4 O60885 1/20 0.43
BRD2 P25440 1/20 0.43
BRD3 Q15059 1/20 0.43
BRDT Q58F21 1/20 0.43
MAP3K14 Q99558 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26235532 0.77 ALDH1A1 (0.44) SMN1; SMN2MAPTDHODHKDM4EPOLB
SCHEMBL24440950 0.76 LMNA (0.44) CNR2CNR1SMN1; SMN2RAB9ALMNA
SCHEMBL4341392 0.73 NPC1 (0.70) SMN1; SMN2MAPTRAB9ADHODHHTT
SCHEMBL1607395 0.72 CNR2 (0.57) CNR2SCN3ASMN1; SMN2MAPTRAB9A
SCHEMBL4347822 0.72 KMT2A (0.68) SMN1; SMN2MAPTRAB9AKDM4EHTT
SCHEMBL14817322 0.71 KDM4E (0.71) CNR2CNR1SCN3ASMN1; SMN2MAPT
SCHEMBL6992210 0.70 CNR2 (0.64) CNR2CNR1SCN3ASMN1; SMN2MAPT
SCHEMBL1607522 0.70 SCN3A (0.71) SCN3ASMN1; SMN2RAB9AKDM4ELMNA
SCHEMBL24440961 0.70 MEN1 (0.76) SMN1; SMN2HTTPOLB
SCHEMBL4350061 0.70 MTOR (0.55) SMN1; SMN2MAPTRAB9AHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827619-B2 Dichlorophenol HSD17B13 inhibitors and uses thereof INIPHARM, INC. (US) 2023-11-28 US disclosed
US-11827619-B2 Dichlorophenol HSD17B13 inhibitors and uses thereof INIPHARM, INC. (US) 2023-11-28 US disclosed
US-20230278981-A1 DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-07 US disclosed
US-20230278981-A1 DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-07 US disclosed
WO-2022103960-A1 DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2022-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278981-A1 DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 CNR2 4212/4885CNR1 3615/4885SCN3A 3626/4885
US-11827619-B2 Dichlorophenol HSD17B13 inhibitors and uses thereof HSD17B1, HSD17B3, HSD17B13 CNR2 4212/4885CNR1 3615/4885SCN3A 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.